日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool

利用综合统计框架和网络工具改进体内药物组合实验的分析

Romero-Becerra, Rafael; Zhao, Zhi; Nebdal, Daniel; Müller, Elisabeth; Bergholtz, Helga; Norum, Jens Henrik; Aittokallio, Tero

Elevated KRAS protein level is associated with better survival in pancreatic cancer

KRAS蛋白水平升高与胰腺癌患者更好的生存率相关

Stålberg, S M; Silwal-Pandit, L; Hamfjord, J; Nebdal, D J H; Lehtiö, J; Lingjærde, O C; Skålhegg, B S; Kure, E H

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab

血液肿瘤突变负荷作为不可切除的非小细胞肺癌患者接受放化疗和度伐利尤单抗治疗的生物标志物

Horndalsveen, Henrik; Haakensen, Vilde Drageset; Madebo, Tesfaye; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Koivunen, Jussi; Oselin, Kersti; Cicenas, Saulius; Helbekkmo, Nina; Aanerud, Marianne; Ahvonen, Jarkko; Silvoniemi, Maria; Bjaanæs, Maria Moksnes; Farooqi, Saima; Nebdal, Daniel; Dalsgaard, Astrid Marie; Danielsen, Britina Kjuul; Børve, Mari; Dalen, Tonje Sofie; Öjlert, Åsa Kristina; Helland, Åslaug

Endometrial carcinomas with ambiguous histology often harbor TP53 mutations.

组织学特征不明确的子宫内膜癌通常携带 TP53 突变

Davidson Ben, Teien Lande Karin, Nebdal Daniel, Nesbakken Anne Jorunn, Holth Arild, Lindemann Kristina, Zahl Eriksson Ane Gerda, Sørlie Therese

Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease

术前血浆氨基酸及其衍生物的分析结果可区分壶腹周围癌和良性疾病。

Stålberg, Stina Margrethe; Silwal-Pandit, Laxmi; Bastani, Nasser Ezzatkhah; Nebdal, Daniel Johan Hammer; Lingjærde, Ole Christian; Skålhegg, Bjørn Steen; Kure, Elin Hegland

Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome

胰腺肿瘤蛋白质组分析表明细胞外基质与患者预后相关

Silwal-Pandit, Laxmi; Stålberg, Stina M; Johansson, Henrik J; Mermelekas, Georgios; Lothe, Inger Marie B; Skrede, Martina L; Dalsgaard, Astrid Marie; Nebdal, Daniel J H; Helland, Åslaug; Lingjærde, Ole Christian; Labori, Knut Jørgen; Skålhegg, Bjørn S; Lehtiö, Janne; Kure, Elin H

Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor

放射疗法联合免疫检查点抑制剂治疗期间T细胞受体库的动态变化

Öjlert, Åsa Kristina; Nebdal, Daniel; Snapkov, Igor; Olsen, Vibeke; Kidman, Joel; Greiff, Victor; Chee, Jonathan; Helland, Åslaug

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

一种独立的、预后不良的乳腺癌亚型,其特征是具有独特的肿瘤免疫微环境。

Tekpli, Xavier; Lien, Tonje; Røssevold, Andreas Hagen; Nebdal, Daniel; Borgen, Elin; Ohnstad, Hege Oma; Kyte, Jon Amund; Vallon-Christersson, Johan; Fongaard, Marie; Due, Eldri Undlien; Svartdal, Lisa Gregusson; Sveli, My Anh Tu; Garred, Øystein; Frigessi, Arnoldo; Sahlberg, Kristine Kleivi; Sørlie, Therese; Russnes, Hege G; Naume, Bjørn; Kristensen, Vessela N

Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors

肿瘤内异质性是导致HER2阳性乳腺癌治疗耐药的关键因素。

Rye, Inga H; Trinh, Anne; Saetersdal, Anna B; Nebdal, Daniel; Lingjaerde, Ole Christian; Almendro, Vanessa; Polyak, Kornelia; Børresen-Dale, Anne-Lise; Helland, Åslaug; Markowetz, Florian; Russnes, Hege G

DNA methylation at enhancers identifies distinct breast cancer lineages

增强子区域的DNA甲基化可识别不同的乳腺癌谱系

Fleischer, Thomas; Tekpli, Xavier; Mathelier, Anthony; Wang, Shixiong; Nebdal, Daniel; Dhakal, Hari P; Sahlberg, Kristine Kleivi; Schlichting, Ellen; Børresen-Dale, Anne-Lise; Borgen, Elin; Naume, Bjørn; Eskeland, Ragnhild; Frigessi, Arnoldo; Tost, Jörg; Hurtado, Antoni; Kristensen, Vessela N